全文获取类型
收费全文 | 2082篇 |
免费 | 140篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 78篇 |
妇产科学 | 55篇 |
基础医学 | 190篇 |
口腔科学 | 69篇 |
临床医学 | 242篇 |
内科学 | 417篇 |
皮肤病学 | 38篇 |
神经病学 | 90篇 |
特种医学 | 268篇 |
外科学 | 327篇 |
综合类 | 54篇 |
预防医学 | 107篇 |
眼科学 | 33篇 |
药学 | 129篇 |
中国医学 | 9篇 |
肿瘤学 | 119篇 |
出版年
2023年 | 16篇 |
2022年 | 8篇 |
2021年 | 54篇 |
2020年 | 31篇 |
2019年 | 49篇 |
2018年 | 62篇 |
2017年 | 57篇 |
2016年 | 49篇 |
2015年 | 62篇 |
2014年 | 63篇 |
2013年 | 90篇 |
2012年 | 95篇 |
2011年 | 114篇 |
2010年 | 93篇 |
2009年 | 94篇 |
2008年 | 81篇 |
2007年 | 72篇 |
2006年 | 64篇 |
2005年 | 41篇 |
2004年 | 47篇 |
2003年 | 46篇 |
2002年 | 36篇 |
2001年 | 35篇 |
2000年 | 33篇 |
1999年 | 31篇 |
1998年 | 59篇 |
1997年 | 55篇 |
1996年 | 72篇 |
1995年 | 51篇 |
1994年 | 46篇 |
1993年 | 52篇 |
1992年 | 25篇 |
1991年 | 15篇 |
1990年 | 29篇 |
1989年 | 46篇 |
1988年 | 44篇 |
1987年 | 37篇 |
1986年 | 42篇 |
1985年 | 31篇 |
1984年 | 17篇 |
1983年 | 22篇 |
1982年 | 22篇 |
1981年 | 17篇 |
1980年 | 11篇 |
1978年 | 12篇 |
1977年 | 18篇 |
1976年 | 17篇 |
1975年 | 14篇 |
1971年 | 16篇 |
1969年 | 8篇 |
排序方式: 共有2236条查询结果,搜索用时 624 毫秒
1.
Fady K. Baddoura Isam W. Nasr Barbara Wrobel Qi Li Nancy H. Ruddle Fadi G. Lakkis 《American journal of transplantation》2005,5(3):510-516
Lymphoid neogenesis is the process by which ectopic lymphoid accumulations that resemble lymph nodes arise in nonlymphoid tissues. Such lymphoid accumulations, known as tertiary lymphoid organs (TLO), are observed in chronic autoimmunity and they propagate immune pathology by setting up local antigen presenting sites. Whether lymphoid neogenesis occurs in transplanted organs and contributes to rejection is not well understood. To begin to address this question, we retrospectively analyzed 319 murine cardiac allografts for microscopic evidence of lymph-node-like structures. We found 78 allografts that had either classical TLO, characterized by discrete T- and B-cell zones and high endothelial venules (HEV) expressing peripheral node addressin (PNAd) (n = 34), or PNAd(+) HEV without organized lymphoid accumulations (n = 44). These changes were present in both short- and long-lived allografts and were invariably associated with rejection. Importantly, they occurred in 78% of allografts undergoing chronic rejection (n = 85) but in only 7% of allografts undergoing primarily acute rejection (n = 184). These findings indicate that, like autoimmunity, alloimmunity is associated with lymphoid neogenesis in the target organ and suggest a role for local T-cell activation in chronic allograft rejection. 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
Five cases of juvenile progressive systemic sclerosis (SSc) are reported (4 girls and 1 boy). The age of onset of the disease ranged from 4 to 13 years. The clinical features included Raynaud's phenomenon present in 4 of 5 cases; hyperpigmentation, skin tightening and contractures of the large joints were noted in all 5 cases. One patient initially diagnosed as having eosinophilic fasciitis developed SSc 3 months later. Another patient was diagnosed initially as having juvenile rheumatoid arthritis. There was one case of pulmonary fibrosis and another of mild restrictive lung disease. Two cases of esophageal and intestinal hypomotility were reported. Scleroderma nephropathy was absent in all 5 cases. 相似文献
7.
8.
9.
10.